GSK’s 5-in-1 Meningococcal Vaccine Candidate Posts Positive Results

GSK’s 5-in-1 meningococcal vaccine combination candidate, administered as two doses given six months apart in healthy individuals, met its 11 primary endpoints in a phase 3 trial, the company said.

The 5-in-1 vaccine candidate prompted a clinically meaningful immune response for all five Neisseria meningitides serogroups (A, B, C, W, and Y) compared to the meningococcal vaccines Bexsero and Menveo in people 10 to 25 years old. The candidate was also well tolerated with a safety profile consistent with Bexsero and Menveo.

If approved, the 5-in-1 vaccine candidate could provide the broadest meningococcal serogroup coverage thus far, and could lead to a simplified immunization schedule, GSK said.

Invasive meningococcal disease, a major cause of meningitis and septicemia, is an uncommon but serious illness that can cause life-threatening complications or even death, typically amongst previously healthy children and adolescents.